SPRB vs. KRON, FGEN, GANX, OVID, IOBT, PRLD, RPTX, STTK, OTLK, and PDSB
Should you be buying Spruce Biosciences stock or one of its competitors? The main competitors of Spruce Biosciences include Kronos Bio (KRON), FibroGen (FGEN), Gain Therapeutics (GANX), Ovid Therapeutics (OVID), IO Biotech (IOBT), Prelude Therapeutics (PRLD), Repare Therapeutics (RPTX), Shattuck Labs (STTK), Outlook Therapeutics (OTLK), and PDS Biotechnology (PDSB). These companies are all part of the "pharmaceutical products" industry.
Spruce Biosciences vs.
Kronos Bio (NASDAQ:KRON) and Spruce Biosciences (NASDAQ:SPRB) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their community ranking, earnings, profitability, institutional ownership, analyst recommendations, valuation, dividends, media sentiment and risk.
Spruce Biosciences received 18 more outperform votes than Kronos Bio when rated by MarketBeat users. However, 65.63% of users gave Kronos Bio an outperform vote while only 54.93% of users gave Spruce Biosciences an outperform vote.
Spruce Biosciences has a net margin of -555.23% compared to Kronos Bio's net margin of -867.66%. Spruce Biosciences' return on equity of -62.10% beat Kronos Bio's return on equity.
Spruce Biosciences has higher revenue and earnings than Kronos Bio. Kronos Bio is trading at a lower price-to-earnings ratio than Spruce Biosciences, indicating that it is currently the more affordable of the two stocks.
Kronos Bio has a beta of 1.79, meaning that its share price is 79% more volatile than the S&P 500. Comparatively, Spruce Biosciences has a beta of 2.38, meaning that its share price is 138% more volatile than the S&P 500.
Kronos Bio presently has a consensus price target of $1.63, suggesting a potential upside of 64.04%. Spruce Biosciences has a consensus price target of $3.90, suggesting a potential upside of 969.08%. Given Spruce Biosciences' higher possible upside, analysts plainly believe Spruce Biosciences is more favorable than Kronos Bio.
In the previous week, Kronos Bio had 1 more articles in the media than Spruce Biosciences. MarketBeat recorded 1 mentions for Kronos Bio and 0 mentions for Spruce Biosciences. Spruce Biosciences' average media sentiment score of 1.00 beat Kronos Bio's score of 0.57 indicating that Spruce Biosciences is being referred to more favorably in the news media.
64.1% of Kronos Bio shares are held by institutional investors. Comparatively, 91.7% of Spruce Biosciences shares are held by institutional investors. 24.4% of Kronos Bio shares are held by company insiders. Comparatively, 9.1% of Spruce Biosciences shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Spruce Biosciences beats Kronos Bio on 11 of the 17 factors compared between the two stocks.
Get Spruce Biosciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for SPRB and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Spruce Biosciences Competitors List
Related Companies and Tools
This page (NASDAQ:SPRB) was last updated on 1/21/2025 by MarketBeat.com Staff
